A phase II study investigating the acute toxicity of targeted intraoperative radiotherapy as tumor-bed boost plus whole breast irradiation after breast-conserving surgery in Korean patients
- 105 Downloads
There are concerns regarding local toxicity when IORT is applied in Asian women with a smaller breast volume than that of Western women. Trials are required to develop safety profiles for this technique. The aim of this trial was to evaluate acute toxicity after intra-operative radiotherapy (IORT) with low-energy X-ray plus whole breast irradiation (WBI) in Asian patients with breast cancer.
This single-arm, single-institute, phase II trial investigated acute toxicity after completion of radiotherapy (targeted IORT followed by WBI) in Korean patients treated with breast-conserving surgery (BCS). In the conventional WBI arm from the TARGIT-A trial, the incidence of acute toxicity within 6 months was 15%. To prove the non-inferiority of the acute toxicity rate, 215 patients were required. This trial is registered with ClinicalTrials.gov (NCT02213991).
Two-hundred and fifteen women were enrolled, and 198 underwent IORT. In 33 patients, clinically significant complications during the acute period were noted. The incidence of acute toxicity was 16.7% (95% CI 11.5–21.9%). There were 29 patients with seroma needing more than 3 aspirations, 4 with wound infection, and 2 with skin breakdown. There was no difference in the rate of complications according to the tumor volume or the tumor-breast volume ratio. Advanced age and high BMI were risk factors for acute complications.
Targeted intra-operative radiotherapy using Intrabeam® is a safe procedure for Korean patients with breast cancer with an acceptable toxicity profile in the acute period.
KeywordsBreast cancer Intra-operative radiotherapy Whole breast irradiation Tumor-bed boost TARGIT Toxicity
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The institutional review boards approved the trial according to their local laws and regulations (IRB No 3-2013-0299). All patients gave written informed consent, and the trial was conducted in compliance with the Helsinki Declaration.
- 2.Darby S, McGale P, Correa C et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716. https://doi.org/10.1016/s0140-6736(11)61629-2 CrossRefGoogle Scholar
- 4.Fisher ER, Anderson S, Redmond C et al (1992) Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. Semin Surg Oncol 8(3):161–166Google Scholar
- 9.Strnad V, Ott OJ, Hildebrandt G et al (2016) 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 387(10015):229–238. https://doi.org/10.1016/s0140-6736(15)00471-7 CrossRefGoogle Scholar
- 10.Vaidya JS, Wenz F, Bulsara M et al (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383(9917):603–613. https://doi.org/10.1016/s0140-6736(13)61950-9 CrossRefGoogle Scholar
- 12.Vaidya JS, Joseph DJ, Tobias JS et al (2010) Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 376(9735):91–102. https://doi.org/10.1016/s0140-6736(10)60837-9 CrossRefGoogle Scholar
- 13.Fastner G, Reitsamer R, Ziegler I et al (2015) IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer—results of a case series after 5-year follow-up. Int J Cancer 136(5):1193–1201. https://doi.org/10.1002/ijc.29064 CrossRefGoogle Scholar
- 15.Forouzannia A, Harness JK, Carpenter MM et al (2012) Intraoperative electron radiotherapy boost as a component of adjuvant radiation for breast cancer in the community setting. Am Surg 78(10):1071–1074Google Scholar
- 21.Bulman AS, Cassoni AM, Ellis H (1985) The functional results following primary treatment of breast cancer with breast conservation. Eur J Surg Oncol 11(3):247–249Google Scholar
- 24.Vrieling C, Collette L, Fourquet A et al (2000) The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol 55(3):219–232CrossRefGoogle Scholar
- 30.Vaidya JS (2017) A comparison of intra-operative radiotherapy boost with external beam radiotherapy boost in early breast cancer (TARGIT-B). https://clinicaltrials.gov/ct2/show/NCT01792726. Accessed 26 Dec 2017